Right on time, the FDA gave its marketing nod to Nektar Therapeutics Inc.'s Movantik (naloxegol) as an oral treatment for opioid-induced constipation (OIC) in adults with chronic noncancer pain, and the peripherally active mu-opioid receptor antagonist (PAMORA) will be available to patients in the first half of next year.